Ms Contin (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Ms Contin, is an opioid analgesic presented as a tablet for oral use. It treats moderate to severe acute pain, chronic cancer pain and severe chronic non‑cancer pain in adult patients.

GNH USA supplies Ms Contin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ms Contin is an opioid analgesic indicated for pain conditions that require strong, sustained relief.

- Moderate to severe acute pain: provides rapid analgesia for postoperative or trauma‑related pain. - Chronic cancer pain: maintains long‑term pain control in patients with malignant disease. - Severe chronic non‑cancer pain: offers sustained relief for conditions such as neuropathic or musculoskeletal pain unresponsive to other therapies.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after dosing. - Constipation: reduced bowel motility, often requiring prophylactic laxatives. - Drowsiness or sedation: mild central nervous system depression. - Dry mouth: decreased salivation leading to discomfort. - Pruritus: mild itching, especially with higher doses. - Miosis: pinpoint pupils as a pharmacologic sign.

Serious or Rare Side Effects: - Respiratory depression: potentially life‑threatening reduction in breathing rate. - Severe hypotension: marked drop in blood pressure, especially with rapid dose escalation. - Opioid dependence or addiction: risk of misuse with prolonged therapy. - Anaphylaxis: rare allergic reaction with rash, swelling, and airway compromise. - adrenal insufficiency: uncommon endocrine disturbance with chronic high‑dose use.

Ms Contin requires careful clinical oversight to balance analgesia with safety.

- Dose titration: adjust dose individually to achieve analgesia while minimizing adverse effects. - Respiratory depression risk: monitor patients with compromised ventilation, especially during initiation. - Constipation: implement prophylactic laxative regimen to prevent bowel obstruction. - Potential for dependence: assess risk factors before initiating therapy and educate patients. - Drug interactions: review concomitant CNS depressants and adjust therapy as needed. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Ms Contin may interact with several medication classes, requiring vigilance.

Major Interactions (Avoid): - Concomitant use with other opioids or strong CNS depressants: may cause profound respiratory depression. - MAO inhibitors: risk of severe opioid toxicity and hypertensive crisis.

Moderate Interactions (Monitor Closely): - Benzodiazepines: increase sedation and respiratory depression; monitor closely. - Anticholinergics: may exacerbate constipation; consider bowel regimen. - SSRIs or SNRIs: potential for serotonin syndrome; observe for signs of agitation or hyperthermia.